Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug save search
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Published: 2022-07-26 (Crawled : 13:20) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 0.25%
H: 200.0%
C: 200.0%
drug candidate research liver pre-clinical therapy cancer publication
Harrow Completes Transfer of the TRIESENCE® New Drug … – Business Wire
Published: 2023-11-29 (Crawled : 12:30) - spacfeed.com
PACI M | $3.77 298.67% 330
|
n/a
|
| O: 8.22%
H: 150.9%
C: 129.46%
triesence drug transfer business
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $745.06 1.88% 0.0% 2M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.27 0.0% 2.6M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Published: 2021-11-18 (Crawled : 12:13) - globenewswire.com
LGVN 4 d | $1.79 -4.28% -4.47% 270K
|
|
| O: 27.4%
H: 139.24%
C: 84.68%
disease food rare pediatric disease designation heart drug lomecel-b designation rare
Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate
Published: 2021-05-24 (Crawled : 14:00) - globenewswire.com
SCPS | $0.1682
|
|
| O: -3.69%
H: 247.56%
C: 78.57%
fda biopharma fda approval drug approval application
Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients
Published: 2020-11-30 (Crawled : 17:31) - jaguarhealth.gcs-web.com
JAGX | News | $0.1691 -6.0% -6.39% 38M
|
Health Technology
|
| O: 2.14%
H: 81.82%
C: 63.12%
covid drug diarrhea commercialization crofelemer
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Published: 2023-01-19 (Crawled : 14:00) - globenewswire.com
SLRX | $0.5118 1.18% 16K
|
Commercial Services
|
| O: 0.0%
H: 75.21%
C: 52.99%
sp-3164 pharmaceuticals drug preclinical molecular
Leading Specialist Material Handling Company, Titan Cranes and Rigging Pty Ltd., Adopts Intelligent Fingerprinting Drug Screening System
Published: 2023-11-30 (Crawled : 08:00) - globenewswire.com
INBS | $2.77 4.14% 3.97% 47K
|
Manufacturing
|
| O: 8.81%
H: 76.26%
C: 51.08%
drug system specialist
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
Published: 2022-12-13 (Crawled : 19:00) - biospace.com/
VINC | $0.955 9.9% 9.01% 410K
|
|
| O: 7.22%
H: 54.99%
C: 48.13%
vip236 fda pharma drug application
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Published: 2024-03-12 (Crawled : 15:00) - globenewswire.com
BGXX | $0.2 0.96% 0.95% 330K
|
|
| O: -0.14%
H: 158.62%
C: 45.93%
drug million expansion
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
Published: 2022-11-22 (Crawled : 14:00) - globenewswire.com
PALI | $5.91 19.88% 16.58% 23M
|
Manufacturing
|
| O: 26.24%
H: 129.03%
C: 44.09%
lb1148 designation drug granted food fast track designation
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
RGLS | $2.25 2.27% 2.22% 100K
|
Health Technology
|
| O: 11.05%
H: 71.96%
C: 40.74%
rgls8429 treatment fda drug disease kidney application therapeutics
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Published: 2022-08-22 (Crawled : 13:20) - biospace.com/
NERV | $2.55 0.0% 4.6K
|
Health Technology
|
| O: 5.96%
H: 57.75%
C: 39.51%
treatment fda drug schizophrenia application roluperidone negative
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
Published: 2022-09-06 (Crawled : 12:20) - globenewswire.com
SPRO | $1.435 2.14% 2.09% 120K
|
Health Technology
|
| O: 14.94%
H: 127.46%
C: 35.28%
drug meeting program therapeutics food update
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
Published: 2023-10-05 (Crawled : 12:00) - biospace.com/
ODYY | $0.0355 354.55% 18K
|
Manufacturing
|
| O: 0.76%
H: 81.0%
C: 34.38%
drug candidate pipeline acquire neurological technology
Clene's ALS Drug Increases Survival by 70% in Mid-stage Study
Published: 2022-07-14 (Crawled : 17:00) - biospace.com/
CLNN S | $0.3352 0.66% 0.66% 310K
|
|
| O: 7.64%
H: 38.71%
C: 33.23%
drug als study
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration
Published: 2022-12-12 (Crawled : 13:00) - biospace.com/
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: 2.19%
H: 34.28%
C: 32.86%
drug meeting therapeutics food
Cell MedX Corp. Files Premarket Notification (510K) with the US Food and Drug Administration and Receives Canadian Trademark Copy
Published: 2021-11-15 (Crawled : 14:00) - cellmedx.com
CMXC | $0.037 -63.33% 39K
|
Manufacturing
|
| O: 1.6%
H: 53.34%
C: 28.64%
food ema drug
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
Published: 2023-09-06 (Crawled : 13:00) - globenewswire.com
ARTL | News | $1.3004 1.87% 15K
|
Health Technology
|
| O: -0.01%
H: 45.95%
C: 27.03%
drug
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
Published: 2023-07-10 (Crawled : 11:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: -2.53%
H: 30.26%
C: 26.24%
mt-401 drug treatment designation aml grants therapeutics
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.